NYSE:EWEdwards Lifesciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Edwards Lifesciences Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $195.42 +6.35 (+3.36 %) (As of 04/7/2020 02:22 AM ET) Add Compare Share Today's Range$189.55Now: $195.42▼$196.2150-Day Range$157.23MA: $200.34▼$235.3152-Week Range$154.52Now: $195.42▼$247.64Volume1.80 million shsAverage Volume1.77 million shsMarket Capitalization$40.87 billionP/E Ratio39.56Dividend YieldN/ABeta0.81 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; Acumen Hypotension Prediction Index, an advanced algorithm that indicates the likelihood of a patient developing hypotension; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingEdwards Lifesciences has received a consensus rating of Buy. The company's average rating score is 2.64, and is based on 15 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $249.33, Edwards Lifesciences has a potential upside of 27.6% from its current price of $195.42.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.9 Community Rank Outperform VotesEdwards Lifesciences has received 1,166 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEdwards Lifesciences has received 820 “underperform” votes. (Add your “underperform” vote.)Community SentimentEdwards Lifesciences has received 58.71% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote “Outperform” if you believe EW will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EW will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,167,916.00 in company stock.Percentage Held by InsidersOnly 1.48% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions82.68% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 19.93% in the coming year, from $5.72 to $6.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 39.56, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 11.84.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 39.56, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.84.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 2.13. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 9.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.77 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:EW Previous Symbol CUSIP28176E10 CIK1099800 Webhttp://www.edwards.com/ Phone949-250-2500Debt Debt-to-Equity Ratio0.16 Current Ratio3.31 Quick Ratio2.60Price-To-Earnings Trailing P/E Ratio39.56 Forward P/E Ratio34.16 P/E Growth2.13 Sales & Book Value Annual Sales$4.35 billion Price / Sales9.40 Cash Flow$6.30 per share Price / Cash Flow31.00 Book Value$19.89 per share Price / Book9.83Profitability EPS (Most Recent Fiscal Year)$5.57 Net Income$1.05 billion Net Margins24.08% Return on Equity31.73% Return on Assets20.14%Miscellaneous Employees13,900 Outstanding Shares209,123,000Market Cap$40.87 billion Next Earnings Date4/28/2020 (Estimated) OptionableOptionable Receive EW News and Ratings via Email Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter. EW Rates by TradingView Edwards Lifesciences (NYSE:EW) Frequently Asked Questions How has Edwards Lifesciences' stock been impacted by COVID-19 (Coronavirus)? Edwards Lifesciences' stock was trading at $197.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EW shares have decreased by 1.0% and is now trading at $195.42. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Edwards Lifesciences? 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 6 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Edwards Lifesciences. When is Edwards Lifesciences' next earnings date? Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Tuesday, April 28th 2020. View our earnings forecast for Edwards Lifesciences. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Corp (NYSE:EW) announced its quarterly earnings results on Thursday, January, 30th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.49 by $0.03. The medical research company had revenue of $1.17 billion for the quarter, compared to analysts' expectations of $1.15 billion. Edwards Lifesciences had a net margin of 24.08% and a return on equity of 31.73%. The business's quarterly revenue was up 20.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.17 earnings per share. View Edwards Lifesciences' earnings history. When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work? Shares of Edwards Lifesciences split on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly issued shares were payable to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split. What guidance has Edwards Lifesciences issued on next quarter's earnings? Edwards Lifesciences issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided EPS guidance of $6.15-6.40 for the period, compared to the Thomson Reuters consensus estimate of $5.98. The company issued revenue guidance of $4.6-5.0 billion, compared to the consensus revenue estimate of $4.70 billion. What price target have analysts set for EW? 22 brokerages have issued 12-month price targets for Edwards Lifesciences' shares. Their forecasts range from $175.00 to $300.00. On average, they anticipate Edwards Lifesciences' stock price to reach $249.33 in the next twelve months. This suggests a possible upside of 27.6% from the stock's current price. View analysts' price targets for Edwards Lifesciences. What are Wall Street analysts saying about Edwards Lifesciences stock? Here are some recent quotes from research analysts about Edwards Lifesciences stock: 1. According to Zacks Investment Research, "Edwards Lifesciences exited the fourth quarter of 2019 on a mixed note with lower-than-expected earnings and a revenue beat. Globally, TAVR procedures increased on strong therapy adoption across all geographies. We are also upbeat about strong sales growth within the Critical Care segment, driven by robust demand for the HemoSphere advance monitoring platform and continued adoption of Smart Recovery. The company continued benefiting from its CASMED acquisition. Moreover, a lifted 2020 EPS guidance raises investors’ optimism on the stock. In the past year, shares of Edwards Lifesciences have outperformed the industry. Meanwhile, dismal performances within Surgical Structural Heart and TMTT segments raise concern. Also, escalating costs put pressure on the margins in the fourth quarter." (2/3/2020) 2. BTIG Research analysts commented, "As we cautioned in our Q1 preview, TAVR results missed Street estimates. While we have no doubt that the underlying market remains strong, results have been light for 4+ quarters now, making us question if the market growth is a tad less than expected or if share is slightly shifting. Even so, management maintained an upbeat tone and there was no change to TAVR guidance but with Boston Scientific’s (BSX, Lotus approved in the U.S. tonight, we have to think that combined with weak Q1 results, shares may see pressure. On longer-term drivers, mitral sales were $4M in Q1 and although early feedback on PASCAL has fostered management’s own confidence in its outlook, we feel hitting $40M in revenue this year is a lofty goal. On the positive side, we would point to management’s bullishness on the revenue ramp in 2H and the solid expense control driving the EPS beat." (4/24/2019) Has Edwards Lifesciences been receiving favorable news coverage? News stories about EW stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Edwards Lifesciences earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutEdwards Lifesciences. Are investors shorting Edwards Lifesciences? Edwards Lifesciences saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 2,322,900 shares, an increase of 7.5% from the February 27th total of 2,160,000 shares. Based on an average daily volume of 1,490,000 shares, the days-to-cover ratio is presently 1.6 days. Approximately 1.1% of the company's stock are sold short. View Edwards Lifesciences' Current Options Chain. Who are some of Edwards Lifesciences' key competitors? Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Insulet (PODD), Masimo (MASI) and Varian Medical Systems (VAR). What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Walt Disney (DIS), Home Depot (HD), Visa (V), Broadcom (AVGO), Mastercard (MA), CVS Health (CVS) and UnitedHealth Group (UNH). Who are Edwards Lifesciences' key executives? Edwards Lifesciences' management team includes the following people: Mr. Michael A. Mussallem, Chairman & CEO (Age 66)Mr. Scott B. Ullem, Corp. VP & CFO (Age 52)Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 57)Mr. Robert W. A. Sellers, Principal Accounting Officer, VP & Corp. ControllerDr. Todd J. Brinton, Corp. VP of Advanced Technology & Chief Scientific Officer What is Edwards Lifesciences' stock symbol? Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW." Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' stock is owned by many different institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.03%), Bath Savings Trust Co (0.01%), Fulton Bank N.A. (0.00%) and RDA Financial Network (0.00%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View institutional ownership trends for Edwards Lifesciences. Which major investors are selling Edwards Lifesciences stock? EW stock was sold by a variety of institutional investors in the last quarter, including Fulton Bank N.A.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem, and William J Phd Link. View insider buying and selling activity for Edwards Lifesciences. Which major investors are buying Edwards Lifesciences stock? EW stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Bath Savings Trust Co, and RDA Financial Network. View insider buying and selling activity for Edwards Lifesciences. How do I buy shares of Edwards Lifesciences? Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Edwards Lifesciences' stock price today? One share of EW stock can currently be purchased for approximately $195.42. How big of a company is Edwards Lifesciences? Edwards Lifesciences has a market capitalization of $40.87 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $5.57 on an earnings per share basis. Edwards Lifesciences employs 13,900 workers across the globe. View additional information about Edwards Lifesciences. What is Edwards Lifesciences' official website? The official website for Edwards Lifesciences is http://www.edwards.com/. How can I contact Edwards Lifesciences? Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected] This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: Yield Curve
